Less is more: Medicines that require less frequent administration improve adherence, but are they better?

PharmacoEconomics

Volumn 24, Issue 3, 2006, Pages 211-213

  Hughes, Dyfrig ^a  

^a BANGOR UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CONTRACEPTIVE AGENT; ESTROGEN; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETONOGESTREL; GESTAGEN; IBANDRONIC ACID; MEDROXYPROGESTERONE; NEUROLEPTIC AGENT; RISPERIDONE;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG COST; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG IMPLANTATION; EDITORIAL; HUMAN; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SCHIZOPHRENIA; UNPLANNED PREGNANCY;

BONE DENSITY CONSERVATION AGENTS; DRUG THERAPY; HUMANS; PATIENT COMPLIANCE; PHARMACEUTICAL PREPARATIONS;

EID: 33644868307     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624030-00001     Document Type: Editorial

References (17)

1. Urquhart J. The odds of the three nons when an aptly prescribed medicine isn't working: non-compliance, non-absorption, non-response. Br J Clin Pharmacol 2002; 54: 212-20
2. Hughes DA, Bagust A, Haycox A, et al. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ 2001; 10: 601-15
3. Haynes RB, Yao X, Degani A, et al. Interventions to enhance medication adherence. Cochrane Database Syst Rev 2005 Oct 19; (4): CD000011
4. Elliott RA, Barber N, Horne R. Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence. Ann Pharmacother 2005; 39: 508-15
5. Claxton AJ, Cramer JA, Pierce C. A systematic review of the association between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-310
6. Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005; 21: 1453-60
7. Richter A, Anton SE, Koch P, et al. The impact of reducing dose frequency on health outcomes. Clin Ther 2003; 25: 2307-35
8. Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005; 20: 1315-22
9. Trussell J. Contraceptive efficacy. In: Hatcher RA, Trussell J, Stewart F, et al., editors. Contraceptive technology. 18th ed. New York: Ardent Media, 2004
10. National Collaborating Centre for Women's and Children's Health. Long-acting reversible contraception: the effective and appropriate use of long-term reversible contraception. London: RCOG Press, 2005
11. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005; 15: 111-7
12. Joint Formulary Committee. British national formulary. 50th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2005 [online]. Available from URL: http://www.bnf.org/bnf/ [Accessed 2006 Jan 23]
13. Haycox A. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models. Pharmacoeconomics 2005; 23 Suppl. 1: 3-16
14. Wetzels GE, Nelemans P, Schouten JS, et al. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens 2004; 22: 1849-55
15. Granger BB, Swedberg K, Ekman I, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet 2005; 366: 2005-11
16. Urquhart J. Pharmacodynamics of variable patient compliance: implications for pharmaceutical value. Adv Drug Deliv Rev 1998; 33: 207-19
17. Summary of product characteristics: Bonviva 150mg film-coated tablets. Welwyn Garden City: Roche Products Limited, 2005 [online]. Available from URL: http://emc.medicines.org.uk/ [Accessed 2006 Jan 23]